We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Baxter International (BAX) Beats on Earnings And Sales in Q3
Read MoreHide Full Article
Headquartered in Deerfield, Illinois, Baxter International Inc. (BAX - Free Report) is a global medical products and services company. The company’s Hospital Products business manufactures products used in the delivery of fluids and drugs to patients. Renal portfolio is mainly for patients with kidney failure/disease and their healthcare providers.
Currently, Baxter International has a Zacks Rank #2 (Buy) but that could change following its third-quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here) We have highlighted some of the key details from the just-released announcement below:
Earnings: Baxter’s adjusted earnings of 64 cents per share beat the Zacks Consensus Estimate of 59 cents and increased by 8 cents from the year-ago quarter.
Revenues: Baxter posted sales of $2.707 billion, beating the Zacks Consensus Estimate for revenues of $2.664 billion. At constant currency (cc), revenues increased almost 6% on a year-over-year basis.
Key Stats: In the reported quarter, Baxter finally completed the acquisition of Claris Injectables Limited. Coming to segmental revenues, hospital products sales increased 7% at cc, while renal products increased 3% from the year-ago quarter.
Major Factors: Hospital Products sales in the quarter were driven by solid sales in the U.S. fluid systems, and select anesthesia and critical care products. Hospital Sales were also favorably impacted by solid demand for injectable pharmaceuticals and hospital pharmacy compounding services. Renal products sales were driven by improved performance across all major product lines and therapies globally.
Meanwhile, Baxter projects fourth quarter revenues to be negatively impacted by approximately $70 million, courtesy of the temporary operational disruptions resulting from Hurricane Maria. Adjusted earnings for the fourth quarter are expected in the band of 56 cents to 59 cents per diluted share.
However, for the full year Baxter estimates sales growth of approximately 4% at cc. Adjusted earnings for the full year are expected in the band of $2.40 to $2.43 per diluted share.
Stock Price: Shares have risen roughly 45.1% year to date, while the broader industry has gained 22.5% over the same time frame. However, following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Baxter International report later!
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Image: Bigstock
Baxter International (BAX) Beats on Earnings And Sales in Q3
Headquartered in Deerfield, Illinois, Baxter International Inc. (BAX - Free Report) is a global medical products and services company. The company’s Hospital Products business manufactures products used in the delivery of fluids and drugs to patients. Renal portfolio is mainly for patients with kidney failure/disease and their healthcare providers.
Currently, Baxter International has a Zacks Rank #2 (Buy) but that could change following its third-quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here) We have highlighted some of the key details from the just-released announcement below:
Earnings: Baxter’s adjusted earnings of 64 cents per share beat the Zacks Consensus Estimate of 59 cents and increased by 8 cents from the year-ago quarter.
Revenues: Baxter posted sales of $2.707 billion, beating the Zacks Consensus Estimate for revenues of $2.664 billion. At constant currency (cc), revenues increased almost 6% on a year-over-year basis.
Baxter International Inc. Price and EPS Surprise
Baxter International Inc. Price and EPS Surprise | Baxter International Inc. Quote
Key Stats: In the reported quarter, Baxter finally completed the acquisition of Claris Injectables Limited. Coming to segmental revenues, hospital products sales increased 7% at cc, while renal products increased 3% from the year-ago quarter.
Major Factors: Hospital Products sales in the quarter were driven by solid sales in the U.S. fluid systems, and select anesthesia and critical care products. Hospital Sales were also favorably impacted by solid demand for injectable pharmaceuticals and hospital pharmacy compounding services. Renal products sales were driven by improved performance across all major product lines and therapies globally.
Meanwhile, Baxter projects fourth quarter revenues to be negatively impacted by approximately $70 million, courtesy of the temporary operational disruptions resulting from Hurricane Maria. Adjusted earnings for the fourth quarter are expected in the band of 56 cents to 59 cents per diluted share.
However, for the full year Baxter estimates sales growth of approximately 4% at cc. Adjusted earnings for the full year are expected in the band of $2.40 to $2.43 per diluted share.
Stock Price: Shares have risen roughly 45.1% year to date, while the broader industry has gained 22.5% over the same time frame. However, following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Baxter International report later!
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Click here for Zacks' secret trade>>